Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cipla Limited
  6. Summary
    CIPLA   INE059A01026

CIPLA LIMITED

(CIPLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
906.2(c) 905.9(c) 911.55(c) 896.35(c) 912 Last
1 360 282 1 941 581 2 723 509 1 360 319 1 073 944 Volume
+0.27% -0.03% +0.62% -1.67% +1.75% Change
More quotes
Estimated financial data (e)
Sales 2022 213 B 2 846 M 2 846 M
Net income 2022 27 858 M 372 M 372 M
Net cash position 2022 25 556 M 341 M 341 M
P/E ratio 2022 25,8x
Yield 2022 0,57%
Sales 2023 232 B 3 088 M 3 088 M
Net income 2023 32 860 M 438 M 438 M
Net cash position 2023 50 624 M 675 M 675 M
P/E ratio 2023 21,9x
Yield 2023 0,62%
Capitalization 723 B 9 645 M 9 643 M
EV / Sales 2022 3,27x
EV / Sales 2023 2,90x
Nbr of Employees 25 672
Free-Float 61,3%
More Financials
Company
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Ratings of Cipla Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about CIPLA LIMITED
10/17Merck COVID-19 pill sparks calls for access for lower income countries
RE
10/08Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19
RE
10/06CIPLA : to Widen Product Portfolio in New Turnaround Plan
AQ
10/05Indian Indices End Higher for Second Consecutive Day on Tuesday; Oil & Natural Gas Soar..
MT
10/04CIPLA : to Acquire Rights to Sell in India Two Diabetes Products of US-based Eli Lilly
MT
10/04Indian Benchmarks Open the Week in Green; Divi's Laboratories Soars 8%
MT
10/04CIPLA : Eli Lilly and Cipla enter into a strategic partnership in India to enhance access ..
PU
10/04India's Divi's Labs hits record high on Merck's positive trial data for COVID-19 drug
RE
10/04CIPLA : to sell Lilly's Trulicity, Humalog diabetes treatments in India
RE
10/04Cipla Limited agreed to acquire Humalog and Trulicity from Eli Lilly and Company Pvt. L..
CI
10/03Eli Lilly and Company Pvt. Ltd. and Cipla Limited Enters into A Strategic Partnership i..
CI
10/01Cipla Limited to Seek Mergers and Acquisitions
CI
09/19CIPLA : Acquires 5% Stake in Indian Nonprofit Healthcare Organization
MT
09/02CIPLA : Partners with Healthcare Startup for Marketing Waterless Technology Products
MT
09/01Indian Indices End Winning Streak on Wednesday; Mahindra & Mahindra Tanks 3%
MT
More news
News in other languages on CIPLA LIMITED
10/05Les indices indiens terminent en hausse pour la deuxième journée consécutive mardi ; le..
10/04Cipla acquiert les droits de vente en Inde de deux produits contre le diabète de la soc..
10/04Les indices indiens ouvrent la semaine dans le vert ; les laboratoires Divi's s'envolen..
09/21INDIA NO COMPRARÁ VACUNAS COVID-19 D : fuentes
09/19Cipla acquiert une participation de 5 % dans une organisation de santé indienne à but n..
More news
Analyst Recommendations on CIPLA LIMITED
More recommendations
Chart CIPLA LIMITED
Duration : Period :
Cipla Limited Technical Analysis Chart | CIPLA | INE059A01026 | MarketScreener
Technical analysis trends CIPLA LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 33
Last Close Price 896,35 INR
Average target price 1 055,91 INR
Spread / Average Target 17,8%
EPS Revisions
Managers and Directors
Umang Vohra Global Chief Executive Officer, MD & Director
Raju Mistry President & Global Chief People Officer
Kedar Upadhye Global Chief Financial Officer
Yusuf Khwaja Hamied Non-Executive Chairman
Jaideep A. Gogtay Global Chief Medical Officer